Shukra Pharmaceuticals to review half-year results, announces new distributorships

Shukra Pharmaceuticals Ltd. announced its board of directors will convene on Thursday, November 13, 2025, to review and approve the unaudited financial results for the half-year ending September 30, 2025. This includes the auditor's limited review report.

In a separate strategic move, Shukra Pharmaceuticals has entered into distributorship arrangements with Seraseal India. These agreements cover the distribution of products to Uttar Pradesh Medical Supplies Corporation Ltd, Gujarat Medical Services Corporation Ltd, and various defence institutions and hospitals across India.

These strategic alliances are aimed at diversifying offerings in medical devices and surgical instruments, expected to significantly boost revenue and business growth. serjeevan singh, director, confirmed these developments, highlighting the company's commitment to expanding its market presence.